---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-26-000020"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:17:38.637479+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q1 revenue $207.7M (+39% YoY); growth products up 56%; reaffirms FY2026 guidance

## Summary
- Total revenues $207.7M, up 39% YoY; combined growth product revenues $149.1M (+56%).
- Qelbree net sales $77.9M (+20%), GOCOVRI $35.2M (+15%), ONAPGO $8.4M, ZURZUVAE collab revenue $27.6M (U.S. sales doubled per Biogen).
- ONAPGO second supplier FDA submission expected Q3 2026; potential approval mid-2027.
- Pipeline: SPN-817 (epilepsy) Phase 2b enrolling; SPN-820 (MDD) Phase 2b ongoing; SPN-443 (ADHD) Phase 1 expected H2 2026.
- Company reiterates full year 2026 financial guidance.

## SEC filing metadata
- accession: 0001356576-26-000020
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000020/0001356576-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000020/supn-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-26-000020
- JSON: https://secwatch.observer/filing/0001356576-26-000020.json
- Plain text: https://secwatch.observer/filing/0001356576-26-000020.txt

## Source-grounded claims
- claim_id: 113379db32da1deeaa28d3bffa7c47e7ab4eb141
  claim: SUPERNUS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: revenue $207.7 million. Guidance reaffirmed.
  evidence_excerpt: Supernus Announces First Quarter 2026 Financial Results • Total revenues were $207.7 million in the first quarter 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657626000020/0001356576-26-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.